The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 73, Issue , 2008, Pages 461-467

  Williams, R T ^a   Sherr, C J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DASATINIB; IMATINIB; NILOTINIB; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; CANCER INHIBITION; CANCER RESISTANCE; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DRUG EFFICACY; HEMATOPOIESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT RESPONSE; ANIMAL; CANCER STEM CELL; CELL PROLIFERATION; DISEASE MODEL; DRUG RESISTANCE; EXPERIMENTAL LEUKEMIA; GENETICS; LEUKEMIA; MOUSE; MUTATION; ONCOGENE; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; REVIEW; TUMOR SUPPRESSOR GENE; CELL SELF-RENEWAL; CELL SPECIFICITY; GENE DELETION; GENE LOCUS; GENE MUTATION; HEMATOPOIETIC STEM CELL;

MUS;

ANIMALS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENES, ABL; GENES, P16; HEMATOPOIESIS; HUMANS; LEUKEMIA; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MUTATION; NEOPLASTIC STEM CELLS; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 68549125516     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2008.73.039     Document Type: Conference Paper

References (35)

1. Arf-/- multipotent progenitors. Nature 453: 228-232.
2. Alvarado, Y., Apostolidou, E., Swords, R., and Giles, F.J. 2007. Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia. Expert Opin. Emerg. Drugs 12: 165-179.
3. Arico, M., Valsecchi, M.G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., Pui, C.-H., and Masera, G. 2000. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. 342: 998-1006.
4. Armstrong, S.A. and Look, A.T. 2005. Molecular genetics of acute lymphoblastic leukemia. J. Clin. Oncol. 23: 6306-6315.
5. Calabretta, B. and Perrotti, D. 2004. The biology of CML blast crisis. Blood 103: 4010-4022.
6. Castor, A., Nilsson, L., Astrand-Grundstrom, I., Buitenhuis, M., Ramirez, C., Anderson, K., Strombeck, B., Garwicz, S., Bekassy, A.N., Schmiegelow, K., et al. 2005. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat. Med. 11: 630-637.
7. Chan, L.C., Karhi, K.K., Rayter, S.I., Heisterkamp, N., Eridani, S., Powles, R., Lawler, S.D., Groffen, J., Foulkes, J.G., Greaves, M.F., and Wiedemann, L.M. 1987. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukemia. Nature 325: 635-637.
8. 1-positive ALL. Science 235: 85-88.
9. Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H.M., Jones, D.L., Visvader, J., Weissman, I.L., and Wahl, G.M. 2006. Cancer stem cells - Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66: 9339-9344.
10. de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Rea, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., et al. 2007. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 109: 1408-1413.
11. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., and Talpaz, M. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344: 1038-1042.
12. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355: 2408-2417.
13. Gleissner, B., Gokbuget, N., Bartram, C.R., Janssen, B., Rieder, H., Janssen, J.W., Fonatsch, C., Heyll, A., Voliotis, D., Beck, J., et al. 2002. Leading prognostic relevance of the BCR-ABL translocation in adult B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99: 1536-1543.
14. Groffen, J., Stephenson, J.R., Heisterkamp, N., de Klein, A., Bartram, C.R., and Grosveld, G. 1984. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93-99.
15. Hochhaus, A., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Apperley, J.F., Druker, B.J., Facon, T., Goldberg, S.L., Cervantes, F., Niederwieser, D., et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronicphase chronic myeloid leukemia after failure of imatinib therapy. Blood 109: 2303-2309.
16. Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., van Lohuizen, M., and Nakauchi, H. 2004. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21: 843-851.
17. Jacobs, J.J.L., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen, M. 1999. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168.
18. Jamieson, C.H., Ailles, L.E., Dylla, S.J., Muijtjens, M., Jones, C., Zehnder, J.L., Gotlib, J., Li, K., Manz, M.G., Keating, A., Sawyers, C.L., and Weissman, I.L. 2004. Granulocytemacrophage progenitors as candidate leukemic stem cells in blast crisis CML. N. Engl. J. Med. 351: 657-667.
19. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. 2006. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354: 2542-2551.
20. Kohno, T. and Yokota, J. 2006. Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: Deduction from structural analysis of breakpoints for deletions. DNA Repair 5: 1273-1281.
21. Ink4a. Nature 448: 943-946.
22. Lessard, J. and Sauvageau, G. 2003. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260.
23. Mullighan, C.G., Williams, R.T., Downing, J.R., and Sherr, C.J. 2008a. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 22: 1411-1415.
24. Mullighan, C.G., Miller, C.B., Radtke, I,, Phillips, L.A., Dalton, J., Ma, J., White, D., Hughes, T.P., Le Beau, M.M., Pui, C.-H., et al. 2008b. BCR-ABL1 lymphoblastic leukemia is characterized by the deletion of Ikaros. Nature 453: 110-114.
25. Nowell, P.C. and Hungerford, D.A. 1960. Chromosome studies on normal and leukemic human leukocytes. J. Natl. Cancer Inst. 25: 85-109.
26. O'Hare, T., Eide, C.A., and Deininger, M.W. 2007. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249.
27. Park, I.-K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and Clarke, M.F. 2003. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302-305.
28. Rowley, J.D. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 243: 290-293.
29. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., and Sawyers,C.L. 2002.MultipleBCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
30. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., and Sawyers, C.L. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
31. Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354: 2531-2541.
32. Williams, R.T., Roussel, M.F., and Sherr, C.J. 2006. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. 103: 6688-6693.
33. +, Arf-null lymphoblastic leukemia. Genes Dev. 21: 2283-2287.
34. Wong, S. and Witte, O.N. 2004. The BCR-ABL story: Bench to bedside and back. Annu. Rev. Immunol. 22: 247-306.
35. Zhao, C., Blum, J., Chen, A., Kwon, H.Y., Jung, S.H., Cook, J.M., Lagoo, A., and Reya, T. 2007. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12: 528-541.